ASH 2022 | Low-molecular-weight heparin as thromboprophylaxis in pregnancy
Saskia Middeldorp, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands, discusses the role of intermediate-dose low-molecular-weight heparin as thromboprophylaxis in pregnant women with venous thromboembolism, and the importance of conducting further clinical trials in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bayer: Honoraria; Pfizer: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria, Research Funding; Abbvie: Honoraria; Viatris: Honoraria; Sanofi: Honoraria; Norgine: Honoraria; GSK: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Astra Zeneca: Honoraria.
